Puma Biotechnology (NASDAQ:PBYI) Director Troy Edward Wilson Sells 10,800 Shares

Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Troy Edward Wilson sold 10,800 shares of the stock in a transaction on Friday, June 12th. The stock was sold at an average price of $7.20, for a total value of $77,760.00. Following the transaction, the director owned 59,750 shares of the company’s stock, valued at $430,200. The trade was a 15.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Puma Biotechnology Trading Down 3.5%

Shares of PBYI stock traded down $0.26 on Monday, hitting $7.07. 177,368 shares of the stock were exchanged, compared to its average volume of 189,537. The firm has a market capitalization of $359.86 million, a PE ratio of 14.73 and a beta of 1.21. Puma Biotechnology, Inc. has a one year low of $3.03 and a one year high of $7.90. The firm’s 50 day moving average is $7.23 and its two-hundred day moving average is $6.57.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.09. The company had revenue of $44.81 million during the quarter, compared to the consensus estimate of $42.00 million. Puma Biotechnology had a return on equity of 20.30% and a net margin of 10.69%. On average, sell-side analysts expect that Puma Biotechnology, Inc. will post 0.28 earnings per share for the current year.

Institutional Trading of Puma Biotechnology

A number of institutional investors have recently added to or reduced their stakes in PBYI. Royal Bank of Canada lifted its holdings in Puma Biotechnology by 244.5% during the 1st quarter. Royal Bank of Canada now owns 4,320 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 3,066 shares in the last quarter. Cerity Partners LLC purchased a new stake in Puma Biotechnology during the 2nd quarter worth about $36,000. BNP Paribas Financial Markets lifted its holdings in Puma Biotechnology by 39.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 2,290 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Puma Biotechnology in the 4th quarter valued at about $49,000. Finally, State of Alaska Department of Revenue purchased a new stake in shares of Puma Biotechnology in the 4th quarter valued at about $50,000. Hedge funds and other institutional investors own 61.29% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Weiss Ratings downgraded Puma Biotechnology from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Wall Street Zen cut Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 16th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat, Puma Biotechnology currently has a consensus rating of “Hold”.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.